Home » Stocks » LabCorp

LabCorp (LH)

Stock Price: $189.05 USD -1.54 (-0.81%)
Updated Aug 14, 2020 1:11 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 18.41B
Revenue (ttm) 11.47B
Net Income (ttm) 362.20M
Shares Out 97.40M
EPS (ttm) 3.71
PE Ratio 50.96
Forward PE 17.04
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $189.05
Previous Close $190.59
Change ($) -1.54
Change (%) -0.81%
Day's Open 190.41
Day's Range 188.48 - 191.12
Day's Volume 167,383
52-Week Range 98.02 - 206.74

More Stats

Market Cap 18.41B
Enterprise Value 24.97B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 97.40M
Float 96.83M
EPS (basic) 3.71
EPS (diluted) 3.71
FCF / Share 12.08
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.96%
FCF Yield 6.38%
Payout Ratio n/a
Shares Short 1.43M
Short Ratio 1.72
Short % of Float 1.67%
Beta 1.41
PE Ratio 50.96
Forward PE 17.04
P/FCF Ratio 15.68
PS Ratio 1.60
PB Ratio 2.47
Revenue 11.47B
Operating Income 781.40M
Net Income 362.20M
Free Cash Flow 1.17B
Net Cash -6.56B
Net Cash / Share -67.32
Gross Margin 28.35%
Operating Margin 6.81%
Profit Margin 3.20%
FCF Margin 10.23%
ROA 4.65%
ROE 4.99%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (19)

Buy 15
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$228.20*
(20.71% upside)
Low
183
Current: $189.05
High
249
Target: 228.20
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11,55511,33310,3089,5538,6806,0125,8085,6715,5425,004
Revenue Growth1.95%9.95%7.9%10.06%44.39%3.5%2.41%2.33%10.76%-
Gross Profit3,2533,1763,0922,8542,9032,2032,2232,2502,2752,098
Operating Income1,3301,3261,3051,2719979049911,024948979
Net Income8248841,227712438511574583520558
Shares Outstanding97.1010110210310184.5087.4094.6099.10102
Earnings Per Share8.358.6111.816.824.355.916.255.995.115.29
EPS Growth-3.02%-27.1%73.17%56.78%-26.4%-5.44%4.34%17.22%-3.4%-
Operating Cash Flow1,4451,3051,4981,197982739819841856884
Capital Expenditures-400-380-313-279-256-204-202-174-146-126
Free Cash Flow1,0459261,185918727536617668710758
Cash & Equivalents338427317434716580404467159231
Total Debt7,1086,0606,7625,8506,3643,0303,0002,6552,2212,188
Net Cash / Debt-6,770-5,633-6,446-5,416-5,648-2,450-2,596-2,188-2,062-1,958
Assets18,04616,18516,67314,24714,1057,3026,9666,7956,1126,188
Liabilities10,4599,1959,8488,7269,1454,4644,4554,0573,5883,701
Book Value7,5676,9716,8045,5064,9452,8212,4912,7172,5042,466
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name LabCorp
Country United States
Employees 65,000
CEO Adam H. Schechter

Stock Information

Ticker Symbol LH
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: LH

Description

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular and infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other procedures. In addition, it provides a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V; and Ciox Health for the creation of COVID-19 patient data registry in the United States. The company was founded in 1971 and is headquartered in Burlington, North Carolina.